Table 1.
Participant characteristics (n = 581).
| Overall (n = 581) | |
|---|---|
| Agea | 46 (38–54) |
| Male sex | 287 (49.4) |
| ABO blood type | |
| A | 249 (43.1) |
| B | 131 (22.7) |
| O | 134 (23.2) |
| AB | 64 (9.9) |
| Rh blood type-positive | 574 (99.3) |
| Symptoms during disease onset | |
| Fever | 458 (84.2) |
| Headache | 205 (37.6) |
| Arthralgia | 133 (24.4) |
| Myalgia | 97 (17.8) |
| Loss of appetite | 117 (21.5) |
| Cough | 235 (42.9) |
| Sputum | 79 (14.5) |
| Hyperemic conjunctiva | 16 (2.9) |
| Sore throat | 121 (22.2) |
| Nasal discharge | 81 (14.9) |
| Chest pain | 62 (11.4) |
| Dyspnea | 105 (19.3) |
| Dysgeusia | 171 (31.4) |
| Dysosmia | 202 (36.9) |
| Diarrhea | 96 (17.6) |
| Nausea and vomiting | 23 (4.2) |
| Fatigue | 255 (46.8) |
| Baseline conditions | |
| Diabetes | 41(7.1) |
| Hypertension | 89 (15.5) |
| Dyslipidemia | 70 (12.1) |
| Highest facilities during disease onset | |
| Hospital admission | 318 (54.8) |
| Isolation facility (e.g., hotels) | 121 (20.9) |
| Home | 141 (24.3) |
| Pneumonia on radiography | 222 (45.9) |
| Severity | |
| Oxygen supplementation | 90 (15.5) |
| Mechanical ventilation | 20 (3.5) |
| ECMO | 7 (1.3) |
| Systemic corticosteroid therapy | 53 (9.3) |
| Days from onset to samplingb | 63 (38–102) |
| Antibody titer (AU/mL) | 33.7 (13.2–73.3) |
a
Numbers of missing data and denominators differ for each item.
b
In the 12 asymptomatic participants, the day of sampling on which the first positive specimen was identified was regarded as the day of onset.ECMO, extracorporeal membrane oxygenation.